ArticleInternational journal of clinical oncology2026
Burden of bladder cancer in China from 1990 to 2023: temporal trends, modifiable risk factors, and implications for prevention.
Article in International journal of clinical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundBladder cancer (BC) is one of the leading causes of cancer death in China. This study analyzed the long-term trends in the disease burden of BC in China from 1990 to 2023, the attributable burden of modifiable risk factors, and conducted a stratified analysis by gender and age.
methodsBased on China data from the Global Burden of Disease Study (GBD) 2023, age-standardized rates and absolute numbers of indicators, such as incidence and mortality of BC were extracted. The Joinpoint regression model was used to calculate the average annual percentage change (AAPC) of indicators for different populations and age groups.
resultsIn 2023, there were 105,632 new cases and 44,729 deaths of BC in China. Compared with 1990, the absolute numbers of incidence and mortality both increased, while the age-standardized mortality and incidence rates showed a decreasing trend, and the prevalence rate slightly rose. Males and individuals aged ≥ 75 years bore the highest disease burden; among the GBD-reported risk factors, smoking contributed the largest attributable burden, and high fasting plasma glucose(FPG) also contributed a measurable burden, with the age-standardized disease burden attributable to them showing a downward trend.
conclusionAlthough the age-standardized incidence, mortality, and DALY rates of BC in China have declined, the absolute burden has increased and remains concentrated among older males. These findings support prioritizing evidence-based primary prevention, especially tobacco control and reduction of carcinogen exposure, while improving risk-adapted awareness and timely diagnostic evaluation in high-burden populations.
Indexed as
Identifiers
42455460What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.